These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27611088)

  • 1. Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.
    Mølbak K; Hansen ND; Valentiner-Branth P
    PLoS One; 2016; 11(9):e0162520. PubMed ID: 27611088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining determinants for reporting suspected adverse events following HPV vaccination in Denmark.
    Ulendorf Jacobsen S; Valentiner-Branth P; Mølbak K
    Vaccine; 2018 Oct; 36(41):6158-6162. PubMed ID: 30201304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital contacts and diagnoses five years prior to HPV vaccination among females referred for suspected adverse vaccine effects: A Danish nationwide case-control study.
    Krogsgaard LW; Bech BH; Plana-Ripoll O; Thomsen RW; Rytter D
    Vaccine; 2019 Mar; 37(13):1763-1768. PubMed ID: 30803841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
    Krogsgaard LW; Petersen I; Plana-Ripoll O; Bech BH; Lützen TH; Thomsen RW; Rytter D
    PLoS Med; 2021 Sep; 18(9):e1003768. PubMed ID: 34495975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
    Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
    Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are unexplained adverse health events following HPV vaccination associated with infectious mononucleosis? - A Danish nationwide matched case-control study.
    Krogsgaard LW; Helmuth IG; Bech BH; Plana-Ripoll O; Lützen TH; Vestergaard HT; Bjerre KD; Thomsen RW; Mølbak K; Rytter D
    Vaccine; 2020 Jul; 38(35):5678-5684. PubMed ID: 32624249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer.
    Klosky JL; Favaro B; Peck KR; Simmons JL; Russell KM; Green DM; Hudson MM
    J Cancer Surviv; 2016 Jun; 10(3):449-56. PubMed ID: 26572902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the contextual nature of vaccine safety monitoring: Adverse events reporting after HPV-vaccination in Denmark, 2015.
    Schartau S; Heering Holt D; Lützen T; Rytter D; Mølbak K
    Vaccine; 2019 May; 37(19):2580-2585. PubMed ID: 30967312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination.
    Morimoto A; Ueda Y; Egawa-Takata T; Yagi A; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Kanzaki H; Nakai H; Mandai M; Yoshino K; Fujita M; Kimura T; Saito J; Sobue T; Nishikawa N; Sekine M; Enomoto T; Horikoshi Y; Takagi T
    Int J Clin Oncol; 2015 Jun; 20(3):549-55. PubMed ID: 25001869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
    Lim ASE; Lim RBT
    Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.